

NOTE

Aranciamycin anhydride, a new anthracycline-type antibiotic isolated from *Streptomyces* sp. Tü 6384*

Jonny Nachtigall^{1,4}, Dirk Schulz^{2,4}, Winfried Beil³, Roderich D Süssmuth¹ and Hans-Peter Fiedler²

The Journal of Antibiotics (2010) 63, 397–399; doi:10.1038/ja.2010.59; published online 16 June 2010

Keywords: anthracycline antibiotic; antitumor activity; *Streptomyces*

Streptomyces isolated from the rhizosphere of Norway spruce were grown in submerged culture in various complex media, and extracts prepared from culture filtrates and biomass were screened by HPLC-diode array analysis to detect novel secondary metabolites.² Strain Tü 6384 was found to produce a new anthracycline-type compound that showed a high similarity with aranciamycin, an antibiotic isolated from *Streptomyces echinatus*, in its UV-visible spectrum.³ The compound was characterized as aranciamycin anhydride (**1**).

Strain Tü 6384 was isolated from the rhizosphere of Norway spruce collected in Rammert forest near Tübingen, Germany. It was examined for a number of key properties that are known to be of value in streptomycete systematics.^{4,5} Whole-cell hydrolysates of strain Tü 6384 contained LL-diaminopimelic acid, and hexa- and octahydrogenated menaquinones with nine isoprene units were the predominant isoprenologs. Partial sequencing of the 16S rRNA gene led to a similarity of 99% with *Streptomyces prunicolor*.

Batch fermentations of strain Tü 6384 were carried out in a 10-l stirred tank fermentor (Biostat S; B Braun, Melsungen, Germany) in a complex medium that consisted of (per liter tap water) oatmeal (Holo Hafergold, Neuform, Germany) 20 g, and 5 ml of a trace element solution that was composed of (per liter deionized water) CaCl₂×2H₂O 3 g, iron(III) citrate 1 g, MnSO₄×1H₂O 200 mg, ZnCl₂ 100 mg, CuSO₄×5H₂O 25 mg, Na₂B₄O₇×10H₂O 20 mg, CoCl₂×6H₂O 4 mg and Na₂MoO₄×2H₂O 10 mg; the pH was adjusted to 7.3 (5 M HCl) before sterilization. The fermentor was inoculated with 5% by volume of a shake flask culture grown in a seed medium at 27 °C in 500-ml Erlenmeyer flasks with a single baffle for 72 h on a rotary shaker at 120 r.p.m. The seed medium consisted of glucose 10 g, glycerol 10 g, oatmeal 5 g, soybean meal (Schoenenberger, Magstadt, Germany) 10 g, yeast extract (Ohly Kat, Deutsche Hefewerke, Hamburg, Germany) 5 g, Bacto Casamino acids 5 g and CaCO₃ 1 g in 1 l tap water. The fermentation was carried out for 4 days with an

aeration rate of 0.5 volume air per volume per min and agitation at 250 r.p.m. The production of **1** reached a maximal yield of 50 mg l⁻¹ at 72 h of incubation. The culture filtrate (**61**) was applied to an Amberlite XAD-16 column (60×4 cm i.d.; Rohm and Haas, Frankfurt, Germany), washed with each of 3 l H₂O and H₂O-EtOH (6:4), and **1** was eluted with 3 l EtOH and concentrated *in vacuo*. The crude product was dissolved in CH₂Cl₂ and added to a diol-modified silica gel column (45×2.6 cm i.d., LiChroprep Diol; Merck, Darmstadt, Germany). The separation was accomplished by a step gradient from CH₂Cl₂ to 5% EtOH. The combined fractions containing **1** were concentrated *in vacuo* and yielded 385 mg crude product, which was purified by preparative RP-HPLC (Nucleosil-100 C-18, 10 μm, 25×1.6 cm i.d.; Maisch, Ammerbuch, Germany) with CH₃CN–0.1% HCOOH using a linear gradient elution from 40 to 80% CH₃CN over 20 min at a flow rate of 20 ml min⁻¹. Compound **1**, 45 mg, was obtained as a red-orange powder (Table 1).

The molecular mass of **1** was determined by high-resolution electrospray ionization-FT-ion cyclotron resonance mass spectrometry, which gave the mass of 710.17728, suggesting a molecular formula of C₃₅H₃₄O₁₆ (theoretical: 709.17741, Δ=0.13 p.p.m.). The chemical structure of **1** as shown in Figure 1 was determined by ¹H-, ¹³C- and 2D-NMR experiments (Table 2) and GC-MS. The complete NMR assignments were unambiguously carried out on the basis of COSY and heteronuclear multiple bond correlation (HMBC) experiments. The ¹H-NMR and heteronuclear single quantum coherence (HSQC) data showed a total of 30 carbon-attached protons, among which five methyl, two methylene and eleven methine carbons could be assigned. Inspection of the 2D-NMR data (COSY, HSQC and HMBC) allowed assignment of the structure of **1**, a new derivative of the aranciamycin family, aranciamycin anhydride (Figure 2). The ¹H-¹H-COSY spectra of **1** revealed protons attached to two ethyl, one phenyl and one sugar (hexose) moiety, as shown by the bold lines in Figure 2. All expected

¹Institut für Chemie, Technische Universität Berlin, Berlin, Germany; ²Mikrobiologisches Institut, Universität Tübingen, Tübingen, Germany and ³Institut für Pharmakologie, Medizinische Hochschule Hannover, Hannover, Germany

⁴These authors contributed equally to this work.

Correspondence: Professor H-P Fiedler, Mikrobiologisches Institut, Universität Tübingen, Auf der Morgenstelle 28, Tübingen 72076, Germany.

E-mail: hans-peter.fiedler@uni-tuebingen.de or Professor RD Süssmuth, Institut für Chemie, Technische Universität Berlin, Straße des 17. Juni 124, Berlin 10623, Germany.

E-mail: suessmuth@chem.tu-berlin.de

*Art. No. 55 in 'Biosynthetic Capacities of Actinomycetes'. Art. No. 54: see ref 1.

Received 18 February 2010; revised 18 March 2010; accepted 11 April 2010; published online 16 June 2010

Table 1 Physico-chemical properties of aranciamycin anhydride¹

	1
Appearance	Red-orange powder
Optical rotation ^a	$[\alpha]^{20}_D +82^\circ$ (c. 0.05, MeOH)
FT-ICR-MS ^b	709.17728 found (M-H) ⁻ 709.17741 calculated (M-H) ⁻ $\Delta=0.13$ p.p.m.
Molecular formula	C ₃₅ H ₃₄ O ₁₆
UV ^c λ_{max} (MeOH) nm (log ϵ)	240 (4.48), 260 (4.44), 435 (4.08)
IR ^d ν_{max} (cm ⁻¹)	3503, 2977, 2933, 1766, 1715, 1675, 1625, 1448, 1415, 1380, 1290, 1247, 1191, 1170, 1135, 1109, 1083, 1031, 1001, 957, 840, 758, 735

Abbreviation: ICR, ion cyclotron resonance.


^aOptical rotation was recorded on a 341 polarimeter (Perkin-Elmer, Überlingen, Germany).

^bHR-FT-ICR-MS measurement was carried out on an APEX II FT-ICR mass spectrometer

(4.7 T, Bruker-Daltonics, Bremen, Germany).

^cUV-visible spectra were obtained on a HP 1090M diode array detector (Agilent Technologies, Waldbronn, Germany).


^dInfrared data measurement was carried out on an 881 IR-spectrometer (Perkin-Elmer).

**Figure 1** Structure of aranciamycin anhydride (**1**).

HMBC correlations of the aranciamycin moiety could be seen and couplings were in good accordance with the data given in literature.⁶ The connection between the sugar moiety and the aranciamycin chromophore was established by the ¹H-¹³C-long-range coupling from C-10 (δ_H 5.19, δ_C 72.4) to H-1'' (δ_H 5.65, δ_C 100.5) and *vice versa* as shown in Figure 2. The constitution of the sugar was determined from COSY and HMBC spectra, which revealed a 6-desoxyhexose moiety. The coupling constants (Table 3) indicated that the sugar was a mannopyranose. A ¹H-¹³C long-range coupling from the methyl group at δ_H 3.56 to C-2'' (δ_C 80.3) of the sugar established the position of the methoxy group. Additional examination of the NMR spectra and chiral GC-MS analysis of the derivatized hydrolysate allowed us to identify the moiety as β -2-O-methyl-L-rhamnose in accordance with the literature.⁷ In comparison with the molecular formula of aranciamycin, derivative **1** has an additional C₈H₆O₄ moiety. In addition, the NMR spectra showed five quaternary olefinic, two methylene and one methyl moiety compared with the aranciamycin core structure. The ¹H-¹³C long-range couplings from H-9'' (δ_H 2.77) to C-8'' (δ_C 171.8), C-10'' (δ_C 19.9) and C-11'' (δ_C 142.0), from H-10'' (δ_H 2.78) to C-8'', C-9'' (δ_C 31.3) and C-14'' (δ_C 165.8), and from H-15'' (δ_H 2.10) to C-11'', C-12'' (δ_C 142.6) and C-13'' (δ_C 166.1) gave rise to an anhydride structure in excellent accordance with literature values.⁸ The connection between the sugar and the anhy-

Table 2 ¹H- and ¹³C-NMR assignment of **1** in CDCl₃-d (25 °C)

Position	δ (¹ H) (p.p.m.) J in Hz	δ (¹³ C) (p.p.m.)
1	7.88 (d, 7.5)	120.9
2	7.75 (t, 7.9)	138.5
3	7.34 (d, 8.3)	125.3
4	—	163.2
5	—	115.9
6	—	193.2
7	—	119.1
8	—	162.5
9	—	133.3
10	5.19 (d, 2.4)	72.4
11	3.72 (d, 2.5)	85.9
12	—	76.9
13	—	198.9
14	—	136.3
15	8.41 (s)	118.0
16	—	134.0
17	—	180.6
18	—	133.6
1'	3.54 (s)	60.3
2'	1.54 (s)	23.1
1''	5.65 (s, br)	100.5
2''	3.53 (dd, 1.4; 3.6)	80.3
3''	3.59 (dd, 3.6; 9.8)	69.6
4''	4.87 (dd, 9.8; 9.8)	75.1
5''	3.92 (dq, 9.8; 6.2)	67.6
6''	1.23 (d, 6.2)	17.7
7''	3.56 (s)	59.0
8''	—	171.8
9''	2.77 (m)	31.3
10''	2.78 (m)	19.9
11''	—	142.0
12''	—	142.6
13''	—	166.1
14''	—	165.8
15''	2.10 (s)	9.7

**Figure 2** ¹H-¹H-COSY and HMBC correlations observed in **1**.

dride moiety was established by the ¹H-¹³C long-range coupling observed from H-4'' (δ_H 4.87) to the carbonyl of C-8'', resulting in the structure of **1** (Figure 1).

Table 3 Growth-inhibitory activity of **1** and aranciamycin ($\mu\text{g ml}^{-1}$) against selected human tumor cell lines

Cell line	1		Aranciamycin	
	GI_{50}	TGI	GI_{50}	TGI
HMO2	6.5	>10	0.62	1.35
HepG2	7.2	>10	1.15	3.2
MCF 7	>10	>10	1.3	3.3

Abbreviations: GI_{50} , 50% growth inhibition; TGI, 100% growth inhibition.

The antimicrobial activity spectrum of **1** was tested in an agar plate diffusion assay against *Bacillus subtilis* DSM 10, *Escherichia coli* K12, *Saccharomyces cerevisiae* ATCC 9010 and *Botrytis cinerea* Tü 157 in a concentration of 0.1–1 mg ml⁻¹. Similar to aranciamycin, **1** showed weak antibacterial activity only against *Bacillus subtilis*. The inhibitory action of **1** on the growth of tumor cells was compared with aranciamycin and tested according to NCI guidelines⁹ with the human tumor cell lines HM02 (gastric adenocarcinoma), MCF 7 (breast carcinoma) and HepG2 (hepatocellular carcinoma). Cells were grown in 96-well microtiter plates in RPMI 1640 with 10% fetal calf serum in a humidified atmosphere of 5% CO₂ in air. Aranciamycin and **1** (0.1–10 $\mu\text{g ml}^{-1}$) were added to the cells after incubation for 24 h. Stock solutions were prepared in DMSO; the final DMSO concentration of the cultures was 0.1%. The cells were fixed and cell protein analyzed with sulforhodamine B after incubation for 48 h. The

cytostatic activity of **1** was somewhat less than that of aranciamycin (Table 3).

ACKNOWLEDGEMENTS

Financial support from the Deutsche Forschungsgemeinschaft (Graduate College 685 'Infection Biology'; DS), the European Commission (project ACTINOGEN, 6th framework, Grant LSHM-CT-2004-005224; RDS), and Bayer Schering Pharma AG (Berlin, Germany) is gratefully acknowledged. We thank Mr A Kulik, Universität Tübingen, for assistance in fermentations.

- 1 Abdel-Mageed, W. M. *et al.* Dermacozines, a new phenazine family from deep-sea dermacocci isolated from a Mariana Trench sediment. *Org. Biomol. Chem.* **8**, 2352–2362 (2010).
- 2 Fiedler, H.-P. Biosynthetic capacities of actinomycetes. 1. Screening for novel secondary metabolites by HPLC and UV-visible absorbance spectral libraries. *Nat. Prod. Lett.* **2**, 119–128 (1993).
- 3 Keller-Schierlein, W., Sauerbier, J., Vogler, U. & Zähler, H. Stoffwechselprodukte von Mikroorganismen—Aranciamycin. *Helv. Chim. Acta* **53**, 779–789 (1970).
- 4 Williams, S. T., Goodfellow, M. & Alderson, G. Genus *Streptomyces* Waksman and Henrici 1943, 339^{AL}. in *Bergey's Manual of Systematic Bacteriology*, Vol. 4 (eds. Williams, S.T. *et al.*) 2452–2492 (Williams & Wilkins, Baltimore, 1989).
- 5 Manfio, G. P., Zakrzewska-Czerwinska, J., Atalan, E. & Goodfellow, M. Towards minimal standards for the description of *Streptomyces* species. *Biotekhnologiya* **8**, 228–237 (1995).
- 6 Bols, M., Binderup, L., Hansen, J. & Rasmussen, P. Inhibition of collagenase by aranciamycin and aranciamycin derivatives. *J. Med. Chem.* **35**, 2768–2771 (1992).
- 7 Keller-Schierlein, W. & Müller, A. The sugar component of aranciamycin: 2-O-methyl-rhamnose. *Experientia* **26**, 929–930 (1970).
- 8 Naganawa, A., Ichikawa, Y. & Isobe, M. Synthetic studies on tautomycin: synthesis of 2,3-disubstituted maleic anhydride segment. *Tetrahedron* **50**, 8969–8982 (1994).
- 9 Grever, M. R., Shepartz, S. A. & Chabner, B. A. The National Cancer Institute: cancer drug discovery and development program. *Semin. Oncol.* **19**, 622–638 (1992).